A new class of drug slows growth of castration-resistant prostate cancer cells

A new class of drug slows growth of castration-resistant prostate cancer cells

This study is the first to show activity for this compound against DEGS and to potentially link inhibition of DEGS to slowing the growth of castration-resistant prostate cancer cells. Treatment with YELIVA™ (ABC294640) increased dihydroceramide levels

(Visited 3 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.